ApoGen Biotechnologies
2014
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Series A
LATEST DEAL TYPE
$11M
LATEST DEAL AMOUNT
10
INVESTORS
Description
Operator of a pharmaceutical and biotechnology company intended to focus on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. The company's pharmaceutical and biotechnology process offers therapies that target key drivers of ongoing DNA mutation and tumor evolution, enabling doctors to break drug resistance in cancer treatment.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Primary Office
- 1616 Eastlake Ave East
- Suite 200
- Seattle, WA 98102
- United States
+1 (206) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ApoGen Biotechnologies’s full profile, request a free trial.
ApoGen Biotechnologies Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 23-Aug-2018 | $11M | 0000 | 000.00 | Completed | Startup |
| 1. Seed Round | Completed | Startup |
ApoGen Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 |
ApoGen Biotechnologies Competitors (34)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gyroscope Therapeutics | Venture Capital-Backed | Stevenage, United Kingdom | 000.00 | 00000000000 | 000.00 | |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 0000000000 | 000.00 |
| 000000000000 | Venture Capital-Backed | Houston, TX | 000.00 | 00000000000 | 000.00 | |
| 000000000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 000000&0 | 00000 |
ApoGen Biotechnologies Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Accelerator Life Science Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Eli Lilly | Corporation | Minority | 000 0000 | 000000 0 |
ApoGen Biotechnologies Executive Team (4)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Daniel Harki Ph.D | Co-Founder | ||
| Reuben Harris Ph.D | Co-Founder | ||
| Thong Le | Chief Executive Officer & Board Member | ||
| John Santini Ph.D | Co-Founder & Board Member |
ApoGen Biotechnologies Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Asish Xavier | ApoGen Biotechnologies | Board Member | 000 0000 | |
| James Sullivan | ApoGen Biotechnologies | Board Member | 000 0000 | |
| Joel Marcus | ApoGen Biotechnologies | Board Member | 000 0000 | |
| John Santini Ph.D | Self | Co-Founder & Board Member | 000 0000 | |
| Johnston Erwin | ApoGen Biotechnologies | Board Member | 000 0000 |